DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20173469

Evaluation of who guided pain management protocol in cases of carcinoma cervix

Jyoti Bindal, Neha Agrawal

Abstract


Background: Pain in patients with cancer cervix is a complex process that occurs from many causes. Opioids, the major class of analgesic used in management of moderate to severe pain, are usually effective and have favorable benefit to risk ratio. Morphine is the most effective and commonly used opioid in cancer pain management.

Methods: Patients of cancer cervix attending the Obstetrics and Gynecology Department, KRH for a period January 2016 to December 2016. 200 patients were included in the study. Pain intensity was measured by visual analogue scale.

Results: Maximum number of subjects were in stage IIB (46%) followed by stage IIIB (42%). Minimum number of subjects were in stage IA and stage IVB. In stage I, 55.6% patients had mild pain, 27.8% had moderate and 16.7% patients had severe pain.  In stage II, carcinoma cervix patients 80.4% patients had moderate pain and only 12% patients had severe pain and stage III, 47.6% patients had severe pain and stage IV all patients had severe pain. Most common site for pain was lower abdomen in carcinoma cervix patients. The pain was recorded as moderate in maximum (49%) subjects followed by severe (39%). Mild pain was seen only in 12% subjects. Maximum response was seen for Step III (95.1%) while minimum for Step II (44.1%).

Conclusions: Pain is a common symptom in cancer cervix patients. Morphine is most useful drug in cancer pain management. It is easily titratable and has a favorable benefit to risk ratio.


Keywords


Cancer cervix, Morphine, Opioids

Full Text:

PDF

References


Portenoy R. Cancer pain: epidemiology and syndromes. Cancer. 1989;63:2298-307.

Venugopal TC, Nandkumar A, Anantha N. Incidence, mortality and survival in cancer cervix in Bangalore India. Br J Cancer. 1995;71:1348-52.

Van den Beuken-van Everdingen MH, De Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-49.

Bonica JJ. Treatment of cancer pain: current status and future needs. In Fhldrc F (eds): Advances in Pain Research and Therapy. New York, NY: Raven Press;1985:589-616.

Singh NU, Srivastava AN, Singh N, Shankhwar PL. Pain management by WHO step ladder pattern protocol in cases of cervical cancer. Era's J Med Res. 2014;1(1):1-6.

Dalmau J, Graus F, Marco M. Hot and dry foot as initial manifestation of neoplastic lumbosacral plexopaty. Neurology. 1989;39:871-2.

McNicol E, Strassels S, Goudas L, Lau J, Carr D. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids for cancer pain a systematic review. J Clin Oncol. 2004;22:1975-1992.

Wilder-Smith C, Schimke J, Osteralder B, Senn H. Oral tarmadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer pain. Ann Oncol. 1994;5:141-6.

Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High dose tramadol in comparison to low dose morphine for cancer pain relief. J Pain Symptoms Manage. 1999;18:174-9.

Hanks GW, Hawkins C. Agreeing a gold standard in the management of cancer pain: the role of poioids. In the effective cancer pain (ed. R. Hillier, I. Finlay, J. Welsh, and A. Miles). London: Aesculapius Medical Press;2000:55-77.